highperformr logo

Avidity Biosciences, Inc.'s Overview

Total employees382
HeadquartersLa Jolla
Founded

Avidity Biosciences, LLC is a biopharmaceutical company pioneering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs)™. Their proprietary AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity is focused on rare muscle diseases and other serious conditions, with a mission to profoundly improve people's lives by revolutionizing the delivery of RNA therapeutics.

Where is Avidity Biosciences, Inc.'s Headquarters?

Avidity Biosciences, Inc. officeAvidity Biosciences, Inc. officeAvidity Biosciences, Inc. officeAvidity Biosciences, Inc. office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters serves as the primary center for research and development, clinical operations, corporate strategy, and administrative functions.

Notable Features:

Features state-of-the-art laboratory facilities for drug discovery and development, modern office spaces designed for collaboration, and proximity to leading research institutions and talent.

Work Culture:

The work culture at Avidity's headquarters is characterized by a strong emphasis on scientific innovation, collaboration, and a patient-centric approach. It fosters a dynamic environment where employees are driven by the potential to make a significant impact on treating rare diseases.

HQ Significance:

The La Jolla headquarters is strategically significant due to its location in a leading biotech cluster, enabling access to a skilled workforce, research collaborations, and essential infrastructure for advancing their AOC platform.

Values Reflected in HQ: The headquarters reflects Avidity's core values of scientific excellence, innovation, urgency in addressing patient needs, and collaboration.

Location:

Avidity Biosciences's global presence is primarily manifested through its clinical trial activities, which are conducted across various countries. They collaborate with international research institutions and investigators to advance their pipeline of AOC therapeutics. As their programs mature, their global operational footprint related to regulatory affairs, manufacturing, and potential commercialization is expected to expand.

Street Address:

10975 North Torrey Pines Road, Suite 150

City:

La Jolla

State/Province:

CA

Country:

USA

Avidity Biosciences, Inc.'s Global Presence

Research Triangle Park, NC, USA

Address: Information not publicly listed; operations primarily centralized in La Jolla. Any additional sites would likely support specific research or clinical operations.

A hypothetical East Coast presence, such as in Research Triangle Park, would offer access to another significant biotech hub, potentially facilitating clinical trial site management, collaborations, or talent acquisition for specific functions.

Buying Intent Signals for Avidity Biosciences, Inc.

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Avidity Biosciences, Inc.

As of April 2025, Avidity Biosciences, Inc.' leadership includes:

Sarah Boyce - President and Chief Executive Officer, Board Member
Michael MacLean - Chief Financial Officer and Chief Business Officer
Simona Rocchi, M.D., Ph.D. - Chief Medical Officer
Arthur A. Levin, Ph.D. - Distinguished Scientist and Senior Advisor
Ranga Ganesan, Ph.D. - Interim Chief Technical Officer
Jihong Liang, Ph.D. - Chief Discovery Officer
Frank C. Sgambato, Pharm.D., M.B.A. - Chief Commercial Officer

Investors of Avidity Biosciences, Inc.

Avidity Biosciences, Inc. has been backed by several prominent investors over the years, including:

RTW Investments
Surveyor Capital (a Citadel company)
Perceptive Advisors
Cormorant Asset Management
EcoR1 Capital
Deerfield Management
Logos Capital
Alexandria Venture Investments
RA Capital Management
Eli Lilly and Company
T. Rowe Price
BlackRock

Executive New Hires/Exits in the Last 12 Months

Hire2
Exits2

Avidity Biosciences has seen key leadership changes aimed at strengthening its clinical development and technical operations capabilities as it advances its pipeline.

Departures

W. Michael Flanagan, Ph.D., W. Michael Flanagan, Ph.D., retired from his role as Chief Technical Officer.
Steve Hughes, M.D., Steve Hughes, M.D., departed from his role as Chief Medical Officer.

New Appointments:

Simona Rocchi, M.D., Ph.D., Dr. Simona Rocchi appointed as Chief Medical Officer, bringing extensive experience in clinical development and medical affairs for rare diseases.
Ranga Ganesan, Ph.D., Ranga Ganesan, Ph.D., appointed as Interim Chief Technical Officer following the retirement of W. Michael Flanagan.

Technology (Tech Stack) used by Avidity Biosciences, Inc.

Discover the tools Avidity Biosciences, Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Avidity Biosciences, Inc. Email Formats and Examples

Avidity Biosciences typically uses a standard corporate email format. The most common format observed is the first initial followed by the last name. Variations might exist but this is a strong primary pattern.

[first_initial][last]@aviditybiosciences.com

Format

jdoe@aviditybiosciences.com

Example

90%

Success rate

News and media

GlobeNewswireMay 21, 2024

Avidity Biosciences Announces Positive Initial Data from FORTITUDE™ Trial Demonstrating First-Ever Successful Targeted Delivery of RNA into Muscle in People Living with Facioscapulohumeral Muscular Dystrophy (FSHD)

Avidity reported positive initial data from the Phase 1/2 FORTITUDE™ trial of del-brax, also known as AOC 1020, in adults with FSHD. The data showed unprecedented targeted delivery of RNA to muscle, substantial reductions in DUX4 regulated genes, and trends of clinical benefit....more

GlobeNewswireMay 7, 2024

Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Avidity Biosciences provided an update on its pipeline programs, including AOC 1001 for DM1, AOC 1020 for FSHD, and AOC 1044 for DMD. The company highlighted upcoming data readouts and its strong financial position to support ongoing development....more

GlobeNewswireMarch 5, 2024

Avidity Biosciences to Share New Long-term Data from MARINA Open-Label Extension Trial of AOC 1001 in Adults with Myotonic Dystrophy Type 1 (DM1) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity announced plans to present new, long-term data from the MARINA-OLE™ trial for AOC 1001 in adults with DM1, showcasing sustained benefits including improvements in myotonia, muscle strength, and patient-reported outcomes....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Avidity Biosciences, Inc., are just a search away.